Boehringer Ingelheim
Boehringer sells drug safety software to ArisGlobal
Phil Taylor
ArisGlobal, Boehringer Ingelheim, digital, digital health, pharmacovigilance, safety
0 Comment
AZ bites back at rivals with new Farxiga data in heart failure
Phil Taylor
AstraZeneca, Boehringer Ingelheim, cardiovascular disease, Eli Lilly, Farxiga, heart failure
0 Comment
News/ News/ Sales and Marketing
Boehringer plans €25bn R&D spend, fuelled by Jardiance
Phil Taylor
Boehringer Ingelheim, Financial, immunology, Jardiance, Oncology, R&D
0 Comment
Jardiance pulls ahead of Forxiga with heart failure approval in EU
Phil Taylor
AstraZeneca, Boehringer Ingelheim, Eli Lilly, Entresto, heart failure, Jardiance, Novartis
0 Comment
Stage set for Jardiance to become universal heart failure drug
Phil Taylor
AstraZeneca, Boehringer Ingelheim, Eli Lilly, Farxiga, heart failure, Jardiance
0 Comment
FDA approves Jardiance (empagliflozin) for wider range of patients with heart failure
Eloise McLennan
Boehringer Ingelheim, Eli Lilly, FDA approval, heart disease, pharma
0 Comment
PureTech challenges Roche’s Esbriet in head-to-head IPF trial
Phil Taylor
Boehringer Ingelheim, Esbriet, fibrosis, idiopathic pulmonary fibrosis, Ofev, PureTech Health, Roche, safety
0 Comment
Boehringer’s spesolimab data raises hope for serious skin disease
Phil Taylor
Boehringer Ingelheim, dermatology, Immunology and inflammation, rare disease, spesolimab
0 Comment